ReviewHealth science reports2026
CD4 Count and Clinical Outcomes of Mpox in People Living With HIV: A Systematic Review and Meta-Analysis.
Review in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: HIV causes immunosuppression by targeting CD4+ T lymphocytes, which may influence susceptibility and clinical outcomes of coinfections such as the Mpox virus (MPXV). Despite conflicting evidence, understanding the relationship between CD4 counts and MPXV severity in people living with HIV (PLWH) remains critical. This study systematically reviews and meta-analyzes available evidence to elucidate this association. Methods: Following PRISMA guidelines, a comprehensive search from a variety of databases was conducted for studies published between January 2014 and August 2025. Inclusion criteria encompassed observational studies reporting on HIV and MPXV co-infection with data on CD4 counts and clinical outcomes. Six studies, including 1254 participants, were included. Data extraction focused on immune parameters, disease severity, and clinical manifestations. The Newcastle-Ottawa Scale assessed study quality, and meta-analyses evaluated pooled associations, heterogeneity, and publication bias. Results: Meta-analysis revealed no statistically significant association between CD4 counts and MPXV disease severity ( Conclusion: CD4 count alone was not found to be a statistically significant factor associated with MPXV severity among HIV-coinfected individuals on ART. Effective viral suppression and immune reconstitution through ART appear protective, emphasizing the need to prioritize ART adherence over reliance on CD4 metrics and validation in well-designed prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.